Peijia Medical (HKG:9996) completed the first patient treatment of the first-in-man clinical trial of ReachTactile robotic-assisted transcatheter aortic valve replacement (TAVR) system on April 2, an April 6 filing with the Hong Kong bourse said.

The procedure was performed by Professor Yan Wang and his team in Xiamen Cardiovascular Hospital of Xiamen University, during which the system was used to implant a TaurusElite(r) transcatheter aortic valve in a patient with severe aortic stenosis.

ReachTactile, the medical device manufacturer's internally developed robotic-assisted TAVR system, offers an innovative solution for TAVR therapy.